Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
11 Agosto 2022 - 3:21AM
Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global
biopharmaceutical company dedicated to the discovery, development,
and commercialization of novel therapies for the treatment of
cancer and related conditions, today announced the pricing of its
underwritten public offering of 35,333,334 shares of its common
stock and accompanying warrants to purchase up to 35,333,334 shares
of common stock at a combined public offering price of $0.75 per
share and accompanying warrant and, in lieu of common stock to
certain investors, pre-funded warrants to purchase up to 4,666,666
shares of its common stock and accompanying warrants to purchase up
to 4,666,666 shares of common stock at a combined public offering
price of $0.749 per share and accompanying warrant . The pre-funded
warrants have an exercise price of $0.001 per share, are
exercisable immediately, and will expire five years following the
date of issuance. The warrants have an exercise price of $1.00 per
share, are exercisable immediately, and will expire five years
following the date of issuance. The gross proceeds to Athenex from
the offering, before underwriting discounts and commissions and
offering expenses, are expected to be approximately $30 million.
The offering is expected to close on August 15, 2022, subject to
customary closing conditions.
Athenex intends to use the net proceeds from the
proposed offering to fund ongoing clinical development for its
product candidates and for working capital and other general
corporate purposes.
SVB Securities is acting as sole
book-running manager for the offering.
The offering is being made only by means of a
previously filed effective registration statement (including a base
prospectus) and a preliminary prospectus supplement. Copies of the
final prospectus supplement and accompanying prospectus, when
available, may also be obtained from: SVB Securities LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or
by email at syndicate@svbsecurities.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there by any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Athenex,
Inc. Founded in 2003, Athenex, Inc. is a
global clinical-stage biopharmaceutical company dedicated to
becoming a leader in the discovery, development, and
commercialization of next generation cell therapy drugs for the
treatment of cancer. In pursuit of this mission,
Athenex leverages years of experience in research and
development, clinical trials, regulatory standards, and
manufacturing. The Company’s current clinical pipeline is derived
mainly from the following core technologies: (1) Cell therapy,
based on NKT cells and (2) Orascovery, based on a P-glycoprotein
inhibitor. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active, accessible,
and tolerable treatments.
Forward Looking
StatementsExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. These forward-looking
statements are typically identified by terms such as “anticipate,”
“continue,” “could,” “expect,” “intend,” “may,” “plan,”
“potential,” “strategy” “will,” and similar expressions. While
Athenex believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in Athenex’s filings with the SEC), many of which are beyond
Athenex’s control and subject to change. Actual results might
differ materially from those explicit or implicit in the
forward-looking statements. Risks and uncertainties include:
changes as a result of market conditions or for other reasons; the
risk that the offering will not be consummated; the exercise of the
warrants to be issued in the offering; the impact of general
economic, health, industrial or political conditions in the United
States or internationally; and other risks and uncertainties
identified in Athenex’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2022 and other subsequent disclosure
documents filed with the SEC. All information provided in this
release is as of the date hereof, and we assume no obligation and
do not intend to update these forward-looking statements, except as
required by law.
ContactsDaniel Lang, MDAthenex,
Inc.Email: danlang@athenex.com
Caileigh DoughertyAthenex,
Inc.Email: cdougherty@athenex.com
Athenex (NASDAQ:ATNX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Athenex (NASDAQ:ATNX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024